CANCER TREATMENT
The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
1 . A method of treating cancer in an individual, the method comprising:
administering to the individual an effective amount of trichostatin A (TSA).
2 . The method of claim 1 , wherein the effective amount is an amount sufficient to decrease an aurora kinase A (AURKA) level in the individual.
3 . The method of claim 1 , wherein the effective amount is an amount sufficient to inhibit histone deacetylase (HDAC) activity and decrease an aurora kinase A (AURKA) level in the individual.
4 . The method of claim 1 , wherein the effective amount is between about 0.1 mg/kg/day and about 10 mg/kg/day.
5 . The method of claim 4 , wherein the effective amount is between about 0.5 mg/kg/day and about 5 mg/kg/day.
6 . The method of claim 5 , wherein TSA is the only AURKA inhibitor administered to the individual.
7 . The method of claim 1 , wherein the cancer includes at least one cancer selected from a group consisting of: breast cancer, gastric cancer, colon cancer, rectal cancer, bladder cancer, pancreatic cancer, ovarian cancer, prostate cancer, lung cancer, hematological cancer, skin cancer, and malignancies.
8 . The method of claim 1 , wherein administering includes orally administering.
9 . The method of claim 1 , wherein administering includes intravenously administering.
10 . A method of treating a cancer in an individual, the method comprising:
determining, from a tumor sample obtained from the individual's body, a level of aurora kinase A (AURKA) expression; and
in the case that the level of AURKA expression is indicative of overexpression, administering to the individual an effective amount of trichostatin A (TSA).
11 . The method of claim 10 , wherein the effective amount is an amount sufficient to decrease an aurora kinase A (AURKA) level in the individual.
12 . The method of claim 10 , wherein the effective amount is an amount sufficient to inhibit histone deacetylase (HDAC) activity and decrease an aurora kinase A (AURKA) level in the individual.
13 . The method of claim 10 , wherein the effective amount is between about 0.1 mg/kg/day and about 10 mg/kg/day.
14 . The method of claim 13 , wherein the effective amount is between about 0.5 mg/kg/day and about 5 mg/kg/day.
15 . The method of claim 10 , wherein TSA is the only AURKA inhibitor administered to the individual.
16 . The method of claim 10 , wherein the cancer includes at least one cancer selected from a group consisting of: breast cancer, gastric cancer, colon cancer, rectal cancer, bladder cancer, pancreatic cancer, ovarian cancer, prostate cancer, lung cancer, hematological cancer, skin cancer, and malignancies.
17 . The method of claim 10 , wherein administering includes orally administering.
18 . The method of claim 10 , wherein administering includes intravenously administering.
19 . A pharmaceutical composition comprising:
trichostatin A (TSA) as a sole or primary aurora kinase A (AURKA) inhibitor; and
a pharmaceutically-acceptable excipient or carrier.
20 . The pharmaceutical composition of claim 19 formulated for oral administration.
21 . The pharmaceutical composition of claim 19 formulated for intravenous administration.
22 . The pharmaceutical composition of claim 19 , comprising TSA in an amount between about 1 mg and about 500 mg.
23 . The pharmaceutical composition of claim 22 , wherein the amount of TSA is equivalent to a dose between about 0.1 mg/kg/day and about 10 mg/kg/day.
24 . The pharmaceutical composition of claim 23 , wherein the amount of TSA is equivalent to a dose between about 0.5 mg/kg/day and about 5 mg/kg/day.
25 . The pharmaceutical composition of claim 22 , wherein the amount of TSA is effective to inhibit histone deacetylase (HDAC) activity.